Patent · US Active

Use of AURKB small-molecule inhibitors for treatment of non-small cell lung cancer

US11840525B2 · kind B2 · utility

0Cited by

1References

1Claims

0Family size

Assignee

NANJING CHINA-AUSTRALIA INSTITUTE OF TRANSLATIONAL MEDICINE CO., LTD. · CN

Inventors

Quan Zhao · Longbeilingcun, CN
Renxiang TAN · 安丰镇, CN
Yadong Wang · Wexford, US
Liping Lin · Xiamen, CN

Key dates

Filing date	Jul 25, 2021
Grant date	Dec 12, 2023
Priority date	—
Expiry date	Apr 3, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D209/08
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

Disclosed is a use of a small-molecule AURKB inhibitor for treatment of non-small cell lung cancer. The small-molecule AURKB inhibitor is directed to a diindolylmethane compound of formula (I-a) or a solvate, a N-oxide or a pharmaceutically acceptable salt thereof,

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.